Ra Capital Management, L.P. Verve Therapeutics, Inc. Transaction History

Ra Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $3.46 Million - $7.19 Million	-310,284 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$31.94 - $54.82 $18.2 Million - $31.2 Million	-570,000 Reduced 64.75%	310,284 $11.4 Million
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $28.1 Million - $53 Million	880,284 New	880,284 $53 Million

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $354M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.